Natera Strengthens Transplant Patient Care with Advanced Prospera Heart Test Enhancement and Launches Innovative Solutions for Breast Cancer and RhD Testing
Austin, Texas - Natera, Inc. a leading global provider of cell-free DNA (cfDNA) and genetic testing, has unveiled groundbreaking advancements in medical technology that are set to transform patient care across multiple fields. The company’s latest innovation, the Prospera Heart with Donor Quantity Score (DQS), significantly enhances the detection of rejection in heart transplant patients. This development aims to revolutionize the monitoring and treatment of transplant recipients, ultimately leading to improved outcomes.
Traditionally, rejection risk in heart transplant recipients has been assessed based on the fraction of donor-derived cell-free DNA (dd-cfDNA) present in the blood compared to the total cfDNA (dd-cfDNA %). However, this approach has its limitations and can be confounded by various factors. Natera’s Prospera Heart with DQS revolutionizes this process by introducing a differentiated new feature. The DQS accurately determines the quantity of donor DNA, providing a more comprehensive and reliable evaluation of rejection risk. This breakthrough technology has the potential to significantly enhance patient care and outcomes in heart transplantation.
Alongside this groundbreaking advancement, Natera has also made significant strides in the field of breast cancer detection and surveillance. Their revolutionary molecular residual disease (MRD) test, Signatera, has demonstrated its ability to detect recurrence early in patients with early-stage breast cancer. The innovative test utilizes personalized and tumor-informed technology, enabling clinicians to monitor the disease’s progression in real-time. The publication of this study in JCO Precision Oncology further solidifies Natera’s position as a leader in the field of genetic testing and personalized medicine.
Additionally, Natera is addressing critical challenges faced by obstetricians and gynecologists (Ob/Gyn) in managing patient care during the nationwide shortage of Rho(D) immune globulin therapy (RhIg). The company has launched a new cfDNA-based fetal RhD test, which accurately determines fetal RhD status using a simple blood sample from pregnant patients as early as nine weeks gestation. This cutting-edge solution empowers healthcare providers to navigate patient care more effectively during the shortage and deliver the best possible outcomes for expectant mothers and their babies.
Natera’s recent advancements in medical technology represent a significant step forward in improving patient care, particularly in the fields of heart transplantation, breast cancer surveillance, and prenatal medicine. By harnessing the power of innovative genetic testing and personalized medicine, Natera is shaping the future of healthcare and revolutionizing the way diseases are detected, monitored, and treated.
Comments